Tirzepatide vs semaglutide for weight loss — a comparison

Key takeaway: Tirzepatide (Zepbound) and semaglutide (Wegovy) are both FDA-approved weekly injectable GLP-1 medications for weight loss. Head-to-head data from the 2025 SURMOUNT-5 trial confirms tirzepatide produces significantly more weight loss on average, though both are effective. The right choice depends on your health history, insurance coverage, and provider evaluation.

Ready to explore your GLP-1 options? Klarity’s licensed providers can evaluate whether semaglutide, tirzepatide, or other weight loss medications may be right for you — fully online, same-day appointments with 2,000+ providers. Many insurance plans may cover your visit. See if you may qualify →

Weight loss drugs with the active ingredient tirzepatide or semaglutide are increasingly popular for chronic weight management as part of a medication-managed approach to weight loss. And if you’re wondering how tirzepatide vs semaglutide (aka Zepbound [tirzepatide] vs Wegovy [semaglutide]) for weight loss compares, you’re in the right place.

What are tirzepatide and semaglutide?

Tirzepatide and semaglutide are the active ingredients in the brand-name weight loss drugs Zepbound and Wegovy, respectively. They’re also the active ingredients in type 2 diabetes injectables Mounjaro (tirzepatide) and Ozempic (semaglutide), and the oral pill for type 2 diabetes, Rybelsus (semaglutide). They are also available as compounded medications.

What is tirzepatide?

Tirzepatide is the active ingredient in Zepbound and Mounjaro. It’s a dual GIP/GLP-1 receptor agonist — it works by mimicking two hormones found naturally in the body to increase satiety, control blood sugar, and support weight loss. Zepbound is available in doses of 2.5, 5, 7.5, 10, 12.5, and 15 milligrams, escalated every 4 weeks.

What is semaglutide?

Semaglutide is the active ingredient in Wegovy and Ozempic. It’s a GLP-1 receptor agonist that mimics the GLP-1 hormone to stimulate insulin production, inhibit glucagon, and slow gut movement. Wegovy comes in doses of 0.25, 0.5, 1.0, 1.7, and 2.4 milligrams, escalated every 4 weeks to a maintenance dose of 2.4 milligrams.

Tirzepatide vs. Semaglutide: Head-to-Head Comparison

How to Get Started with Tirzepatide or Semaglutide at Klarity

Tirzepatide vs semaglutide: side effects

Like any medication, tirzepatide and semaglutide can cause side effects. Common side effects for both include nausea, diarrhea, vomiting, constipation, stomach pain, and fatigue. Both carry a boxed warning for thyroid cancer and should not be used by those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome.

2026 Update: New Data and Formulations

The GLP-1 landscape has evolved significantly in 2025-2026 with several updates directly relevant to patients comparing tirzepatide vs semaglutide.

SURMOUNT-5 head-to-head results (2025). This landmark direct-comparison trial confirmed that tirzepatide produced approximately 47% greater body weight reduction than semaglutide in adults with obesity over a comparable treatment period — the first robust head-to-head evidence in patients without type 2 diabetes. For patients deciding between the two, this data favors tirzepatide for maximum weight loss, though individual response varies.

Oral semaglutide for weight loss approved (2026). The FDA approved higher-dose oral semaglutide (Rybelsus formulation) for chronic weight management in early 2026. This adds an injection-free semaglutide option, though GI side effects persist and bioavailability is lower than the injectable form. Suitable for patients who prefer daily pills over weekly injections.

Retatrutide Phase 3 underway. The triple agonist retatrutide (targeting GLP-1, GIP, and glucagon receptors) is in Phase 3 trials with early data showing up to 24% body weight reduction — potentially exceeding both current agents. Expected to seek FDA approval in 2026-2027.

Insurance coverage expanding. Under discussions tied to the Treat and Reduce Obesity Act, several major commercial insurers expanded GLP-1 obesity coverage in 2025-2026. Verifying current benefits before booking is more important than ever, as coverage varies significantly by plan. Coverage varies by plan. Verify your benefits before booking.

Frequently Asked Questions

Is tirzepatide better than semaglutide for weight loss?

Current evidence, including the 2025 SURMOUNT-5 trial, indicates tirzepatide produces greater average weight loss than semaglutide. However, individual responses vary and the best medication for you depends on your health history, tolerance, and insurance coverage. A licensed provider can help determine which option may be appropriate.

Can I switch from semaglutide to tirzepatide?

Yes, many patients switch between GLP-1 medications. The transition should be managed by a licensed provider who can guide appropriate dosing during the switch to minimize side effects.

Does insurance typically cover tirzepatide or semaglutide for weight loss?

Coverage varies widely by plan. Many commercial plans may cover one or both medications when prescribed for obesity with qualifying BMI criteria. Some plans cover one but not the other. Coverage varies by plan. Verify your benefits before booking.

How do I get evaluated for a GLP-1 medication online?

Klarity’s 2,000+ licensed providers offer fully online evaluations for tirzepatide and semaglutide, with same-day appointments often available. A provider reviews your health history and determines if a GLP-1 medication may be appropriate for you.

What is retatrutide and when will it be available?

Retatrutide is a next-generation triple agonist (GLP-1, GIP, glucagon) currently in Phase 3 clinical trials. Early data shows up to 24% body weight reduction. It is not yet FDA-approved but may seek approval in 2026-2027.

Ready to explore your GLP-1 options? Klarity’s licensed providers can evaluate whether semaglutide, tirzepatide, or other weight loss medications may be right for you — fully online, same-day appointments with 2,000+ providers. Many insurance plans may cover your visit. See if you may qualify →

Coverage varies by plan. Verify your benefits before booking.